# US 2003/0077658 A1 · Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077658 A1
- Document ID: US20030077658A1
- Status: Published application
- Kind: A1
- Application number: 10/053,669
- Filed: 2002-01-24
- Published: 2003-04-24
- Earliest claimed: 1999-03-10
- Assignees: Magnesium Diagnostics, Inc.
- Inventors: Ibert C. Wells
- Web page: https://patentgrep.com/patent/US20030077658A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/321: Arterial hypertension
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to methods for detecting the deficiency of magnesium tightly bound to cellular membranes, i.e., magnesium binding defect, which deficiency is associated with certain abnormal physiological states, e.g., salt-sensitive essential hypertension or Type 2 diabetes mellitus.

## Claims

### Claim 1

A monoclonal or polyclonal antibody having high affinity for a peptide selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).

### Claim 2 (depends on 1)

The antibody of claim 1, wherein said antibody is a monoclonal antibody.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein said antibody has high affinity for the peptide Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1).

### Claim 4 (depends on 2)

The antibody of claim 2, wherein said antibody has high affinity for the peptide Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1).

### Claim 5 (depends on 1)

The antibody of claim 1, wherein said antibody has high affinity for the peptide Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4).

### Claim 6 (depends on 2)

The antibody of claim 2, wherein said antibody has high affinity for the peptide Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4).

### Claim 7 (depends on 1)

The antibody of claim 1, wherein said antibody has high affinity for the peptide Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).

### Claim 8 (depends on 2)

The antibody of claim 2, wherein said antibody has high affinity for the peptide Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).

### Claim 9 (depends on 1)

The antibody of claim 1, wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).

### Claim 10 (depends on 2)

The antibody of claim 2, wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).

### Claim 11

A method for detecting magnesium binding defect comprising:
a) measuring in blood serum the level of peptide having an amino acid sequence selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2); and
b) comparing said level to a standard,
wherein a reduced level of said peptide is indicative of said magnesium binding defect.

### Claim 12 (depends on 11)

The method of claim 11, wherein said level of peptide is measured by using an antibody to peptide having an amino acid sequence selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).

### Claim 13 (depends on 12)

The method of claim 12, wherein the antibody is monoclonal.

### Claim 14 (depends on 13)

The method of claim 13, wherein the monoclonal antibody cross reacts with each of said peptides.

### Claim 15 (depends on 12)

The method of claim 12, wherein the antibody is employed in an immunoenzyme assay.

### Claim 16 (depends on 15)

The method of claim 15, wherein the immunoenzyme assay is enzyme-linked immunosorbent assay to quantitate the concentration of said peptide in blood serum.

### Claim 17 (depends on 12)

The method of claim 12, wherein the antibody is polyclonal.

### Claim 18

A method for correcting magnesium binding defect of an individual comprising administering to said individual peptide having an amino acid sequence selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).

### Claim 19 (depends on 18)

The method of claim 18, wherein said peptide is administered in an amount sufficient to correct magnesium binding defect.

### Claim 20 (depends on 19)

The method of claim 19, wherein the peptide is administered intravenously.
